Canaccord Adams
http://www.canaccordadams.com/default.htmCanaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, their 225 professionals seek out emerging opportunities in their key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, their experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.
View Older Stories View More Recent Stories
-
Canaccord Adams Reiterates a 'Buy' on ATP Oil & Gas Corporation (ATPG); We Would Be Buyers
-
Canaccord Adams Downgraded GMX Resources (GMXR) to Hold; Downtrend Continues
-
Canaccord Adams & Morgan Keegan Downgrade GMX Resources (GMXR)
-
Canaccord Adams Maintains a 'Buy/Best Idea' Rating on Metalico (MEA); Raises PT & 2010 EPS Estimates
-
Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Still Best Idea
-
Canaccord Adams Reiterates a 'Buy' on Constant Contact (CTCT); Still Best Idea; Build Position At Current Levels
-
Notable Analyst Rating Changes 03/12: ARO, NSM, CBEY, SCCO, TVL Upgraded; HBC, NRG, NFLX, SKIL, PSUN, SAAS Downgraded
-
AVEO Pharmaceuticals (AVEO) IPO Trades Lower
-
Daily State of the Markets 3/12: Follow the (New) Leader?
-
AVEO Pharma (AVEO) Prices 9M Common IPO at $9/Share
-
Canaccord Adams Reiterates a 'Buy' on SunOpta (STKL); Raises PT
-
Canaccord Adams Reiterates a 'Buy' on Semtech (SMTC); Raises Estimates
-
Canaccord Adams Reiterates a 'Buy' Rating on Approach Resources (AREX)
-
Canaccord Adams Reinstates a 'Buy' on Suncor Energy (SU), Adjusts PT & Estimates
-
Analysts Giddy About InterMune (ITMN) On Expected Pirfenidone Approval
-
Canaccord Adams Reiterates a 'Buy' on ICF International (ICFI); Strong Q4 Results; Maintain 2010 Estimates
-
Canaccord Adams Reiterates a 'Buy' on InterMune (ITMN); FDA Approval, Focus Shifts to Market Opportunity
-
Canaccord Adams Initiates Coverage on Netflix (NFLX) with a Buy; DVD-by-Mail Isn't Going Away
-
Canaccord Adams Initiates Coverage on Coinstar (CSTR) with a Buy
-
Canaccord Adams Maintains a 'Hold' on Superior Well Services (SWSI); Lowers 2011 Estimates
-
Notable Analyst Rating Changes 03/10: ITMN, RDN, EIX, IFSIA Upgraded; FACT, VALE, PSS, NLY, AVAV Downgraded
-
Canaccord Adams Lifts Price Target On Intermune (ITMN) to 'Street High' $66/Share
-
Canaccord Adams Initiates Coverage on China XD Plastics (CXDC) with a Buy; Recent Dip Presents Excellent Buying Opportunity
-
Canaccord Adams Maintains a 'Buy' on Horsehead Holding (ZINC); Raises Estimates & PT
-
Canaccord Adams Maintains a 'Buy' on Texas Instruments (TXN); Raises Estimates
-
Canaccord Adams Maintains a 'Buy' on Northern Oil and Gas (NOG), Raises PT
-
Canaccord Adams Maintains a 'Buy' on Fuel Systems Solutions (FSYS); Tweaks Estimates & PT
-
Canaccord Adams Maintains a 'Buy' on Fuel Tech (FTEK); Raises PT & Estimates
-
SinoHub (SIHI) Completes 1.63M Private Placementat $3.00/Share
-
What is Research In Motion (RIMM) Worth?
-
Canaccord Adams Maintains a 'Buy' on Fuel Systems Solutions (FSYS)
-
Canaccord Adams Reiterates a 'Buy' on Summer Infant (SUMR); Raises PT & Estimates
-
Canaccord Adams Reiterates a 'Hold' on IRIS International (IRIS); Lowers PT & Estimates
-
Canaccord Adams Reiterates a 'Buy' Rating on AMAG Pharmaceuticals (AMAG); Lowers PT
-
Canaccord Adams Maintains a 'Hold' on Allos Therapeutics (ALTH); Raises PT & Estimates
-
Notable Analyst Rating Changes 03/02: DELL, MRVL, SNDK, SQNM Upgraded; KMB, NUHC, OSIP, PALM Downgraded
-
Canaccord Adams Downgrades OSI Pharmaceuticals (OSIP) to Hold on Aggressive Tender Offer
-
Green Energy Could Put Green in Your Wallet - Barron's (CSCO, ABB, GOOG, MSFT, More...)
-
Canaccord Adams Reiterates a 'Buy' Rating on ev3 (EVVV); Added to Best Ideas List
-
Canaccord Adams Maintains a 'Buy' on Fuel Tech (FTEK); Raises PT, Comments on Q4
-
Canaccord Adams Reiterates a 'Buy' on Rosetta Resources (ROSE); Several Catalysts
-
Canaccord Adams Maintains a 'Buy' on Brigham Exploration (BEXP); Announces Positive 2010 Outlook
-
Canaccord Adams Sees Deteriorating Feature Phone Segment at Nokia (NOK), Places Rating Under Review
-
Daily State of the Markets 3/1: Bend But Don't Break
-
Canaccord Adams Lifts Price Target On Research In Motion (RIMM) to $100
-
Canaccord Adams Lifts Q2 Estimates on Apple (AAPL), But Says Verizon iPhone Launch and iPad To Be Delayed
-
Trius Therapeutics (TSRX) Sees IPO Price of $12-$14
-
Canaccord Adams Maintains a 'Buy' on Medicis Pharmaceutical (MRX); Adjusts PT & Estimates
-
Canaccord Adams Maintains a 'Buy' on NuVasive (NUVA); Q4/09 Results Bring More Questions Than Answers; Guidance Complicated
-
Canaccord Adams Maintains a 'Hold' on LKQ Corporation (LKQX); Raise PT & Estimates

